Albireo Pharma, Inc.

Report topline results for lead candidate A3907

Deadline passed; outcome being checked

Announced: 25 Feb 2021
Due: 31 Dec 2021
Status: Checking

Deadline
Met
Late
Not met
Today

What the company said

“having completed IND-enabling studies with plans for Phase 1 study initiation by end of the first quarter and topline results by the end of the year”

SourceAlbireo Pharma, Inc. Form 8-K press release, 2021-02-25
FilingSEC filing index
Deadline as statedby the end of the year
Deadline used31 Dec 2021, the last day of the stated period
TypeProject
Permanent referenceKI-C-2021-C322505-024429
Cite as https://keptindex.org/c/KI-C-2021-C322505-024429/ — this address never changes.

What we found

The deadline has passed. We check for public evidence starting 30 days after the deadline, and repeat the check if nothing clear turns up.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout
Indicative materiality: Medium rules
Action: Report
Deliverable: Topline results for A3907
Language: Expected (“expects”, “plans”)
In the company’s control: High
Specificity: Medium

Tell me what happens

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Alert me when this resolves

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Albireo Pharma, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-C322505-024429 · Corrections policy